RiverVest Venture Partners overview
Stories about RiverVest Venture Partners
RiverVest adds MD and senior associate to team
RiverVest Venture Partners has named Derek Rapp as managing director and Dr. Isaac Zike as senior associate. Previously, Rapp was president and CEO of JDRF while Zike was a life sciences associate at Huron Consulting Group.
ScoutBio raises $20 mln
ScoutBio said April 10 that it raised $20 million in Series B financing co-led by Digitalis Ventures’ Companion Fund and RiverVest Venture Partners. GreenSpring Associates as well as existing investors Frazier Healthcare Partners, Adage Capital Management and Correlation Ventures participated in the round. ScoutBio is a biotech focused on pet medicine that aims to deliver a pipeline of one-time therapeutics for major chronic pet health conditions.
RiverVest appoints CFO
RiverVest Venture Partners has named Sivan Weitzman as chief financial officer. Previously, she was the CFO at Halman Aldubi Investment House.
RiverVest closes fourth fund at $184.4 mln
RiverVest Venture Partners, a life sciences venture firm, has closed its oversubscribed fourth fund at $184.4 million. According to the firm, RiverVest has funded 47 and exited or taken public 22 life science companies.
RiverVest Venture Partners rakes in over $167 mln for fourth fund
RiverVest Venture Partners has raised over $167 million for its fourth fund, according to an SEC filing https://www.sec.gov/Archives/edgar/data/1725443/000172544318000001/xslFormDX01/primary_doc.xml With offices in St. Louis, Cleveland and San Diego, the venture firm invests in life science companies.
Cardialen takes in $17 mln Series B
Minneapolis-based Cardialen Inc, a medical device company, has raised $17 million in Series B funding. RiverVest Venture Partners led the round with participation from Qiming Venture Partners, HBM Healthcare Investments and Cultivation Capital.
OncoResponse grabs $40 mln Series B
Houston, Texas-based OncoResponse, an immunotherapy company, has closed $40 million in Series B financing. RiverVest Venture Partners led the round.
RiverVest to raise $150 mln fourth venture fund
RiverVest Venture Partners has set out to raise a $150 million fourth venture fund, according to a filing with the SEC.
RiverVest Venture Partners contact information
Offices
101 S. Hanley Road, Suite 1850, St. Louis, 63105, United StatesContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Ms. Sivan Weitzman | Job titleChief Financial Officer | LocationSt. Louis, United States | Email  -------- |
| Mr. Thomas C. Melzer | Job titleCo-Founder and Managing Director | LocationSt. Louis, United States | Email ----- |
| Mr. Derek K. Rapp | Job titleManaging Director | LocationSt. Louis, United States | Email ----------- |
| Dr. John McKearn | Job titleManaging Director | LocationSt. Louis, United States | Email ---------- |
RiverVest Venture Partners funds managed
Closed funds: 6
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size ----------- | Close dateMar 2021 | Strategy ---------- | |
Fund size ---------- | Close dateDec 2018 | Strategy --------- | |
Fund size ------- | Close dateDec 2016 | Strategy ----------- | |
Stories that mention RiverVest Venture Partners
Biolinq attracts $100m Series B
Biolinq Incorporated, a medical device company, has secured $100 million in Series B financing.
Sparrow Pharmaceuticals rings in $50m Series A
Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company, has raised $50 million in Series A financing.
VC-backed Spruce Biosciences adds CFO and VP to team
San Francisco-based Spruce Biosciences, a developer of novel therapies for rare endocrine disorders, has named Samir Gharib as chief financial officer and Dr. Dasharatha Reddy as vice president of pharmaceutical development and manufacturing.
Avalyn Pharma nets $35.5m Series B
Seattle-based Avalyn Pharma Inc, a biopharmaceutical company focused on treating life threatening pulmonary diseases, has secured $35.5 million in Series B financing.
Adarza BioSystems garners $25 mn Series D
St. Louis, Missouri-based Adarza BioSystems, a biotech firm, has secured $25 million in Series D funding.
VC-backed Mirum Pharmaceuticals debuts IPO
Foster City, California-based Mirum Pharmaceuticals, a clinical-stage therapeutics company focused on treating cholestatic liver diseases, has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading July 18, 2019 on the NASDAQ under the ticker symbol "MIRM." Citigroup, Evercore ISI and Guggenheim Securities are the lead underwriters. Mirum's pre-IPO backers included NEA, Deerfield Management, Frazier Healthcare Partners, Novo Holdings, Pappas Capital, RiverVest Venture Partners and Rock Springs Capital.